Skip to main content

Table 1 Correlations between serum methylated septin 9 gene and clinico-pathological features of colorectal cancer patients (n = 144) (Chi square and Fisher’s tests)

From: Methylated septin 9 gene is an important prognostic marker in stage II and stage III colorectal cancer for evaluating local recurrence or distant metastasis after surgery

Parameter Negative group (%) Positive group (%) P
Gender
Male 31(36.0) 55(64.0) 0.121
Female 29(50.0) 29(50.0)  
Age
60 yr 26(41.9) 36(58.1) 0.955
 >60 yr 34(41.5) 48(58.5)  
T stage
 T1 7(87.5) 1(12.5)  < 0.001
 T2 13(76.5) 4(23.5)  
 T3 18(45.0) 22(55.0)  
 T4 22(27.8) 57(72.2)  
N stage
 N0 38(46.3) 44(53.7) 0.116
 N1 13(46.4) 15(53.6)  
 N2 9(26.5) 25(73.5)  
Distant metastasis (M)
 M0 58(49.6) 59(50.4)  < 0.001
 M1 2(7.4) 25(92.6)  
TNM stage
 I 19(82.6) 4(17.4)  < 0.001
 II 19(38.8) 30(61.2)  
 III 20(44.4) 25(55.6)  
 IV 2(7.4) 25(92.6)  
Vascular invasion
 Absent 51(47.7) 56(52.3) 0.020
 Present 9(24.3) 28(75.7)  
Histologic grade
 Low level 1(7.1) 13(92.9) 0.006
 Medium level 57(44.9) 70(55.1)  
 High level 2(66.7) 1(33.3)  
Location
 Right Colon 10(30.3) 23(69.7) 0.064
 Left Colon 16(34.8) 30(65.2)  
 Rectum 34(52.3) 31(47.7)  
Microsatellite
 pMMR 59(45.0) 72(55.0) 0.008
 dMMR 1(7.7) 12(92.3)  
  1. pMMR: proficient mismatch repair; dMMR: deficient mismatch repair